Azacitidine versus decitabine in patients with refractory anemia with excess blast-Results of multicenter study.

Autor: Salim O; Akdeniz University, School of Medicine, Department of Hematology, Antalya, Turkey. Electronic address: ozansalim@gmail.com., Toptas T; Marmara University, School of Medicine, Department of Hematology, Istanbul, Turkey., Avsar E; Akdeniz University, School of Medicine, Department of Hematology, Antalya, Turkey., Yucel OK; Akdeniz University, School of Medicine, Department of Hematology, Antalya, Turkey., Ozturk E; Koc University, School of Medicine, Department of Hematology, Istanbul, Turkey., Ferhanoglu B; Koc University, School of Medicine, Department of Hematology, Istanbul, Turkey., Geduk A; Kocaeli University, School of Medicine, Department of Hematology, Kocaeli, Turkey., Mehtap O; Kocaeli University, School of Medicine, Department of Hematology, Kocaeli, Turkey., Tombak A; Mersin University, School of Medicine, Department of Hematology, Mersin, Turkey., Tiftik EN; Mersin University, School of Medicine, Department of Hematology, Mersin, Turkey., Deveci B; Antalya Training and Research Hospital, Department of Hematology, Antalya, Turkey., Kurtoglu E; Antalya Training and Research Hospital, Department of Hematology, Antalya, Turkey., Kara O; Marmara University, School of Medicine, Department of Hematology, Istanbul, Turkey., Atagunduz IK; Marmara University, School of Medicine, Department of Hematology, Istanbul, Turkey., Tuglular TF; Marmara University, School of Medicine, Department of Hematology, Istanbul, Turkey., Undar L; Akdeniz University, School of Medicine, Department of Hematology, Antalya, Turkey.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2016 Jun; Vol. 45, pp. 82-9. Date of Electronic Publication: 2016 Apr 11.
DOI: 10.1016/j.leukres.2016.04.003
Abstrakt: The present study aimed to compare the efficacy and safety of azacitidine and decitabine in patients with myelodysplastic syndrome (MDS). A total of 88 patients diagnosed with refractory anemia with excess blast (RAEB) treated with azacitidine (n=57) or decitabine (n=31) were evaluated. Comparisons between azacitidine and decitabine groups were performed in the whole cohort, and in a 1:1 propensity score-matched cohort in order to reduce the simple selection bias. Patients who received azacitidine or decitabine had comparable overall response rates in both the unmatched (49.1% vs. 64.5%, p=0.166) and the propensity-matched cohorts (52% vs. 68%, p=0.248). The cumulative incidence of AML transformation at one year was comparable between azacitidine and decitabine in the unmatched (24.0% vs. 31.3%, p=0.26) and in the propensity-matched cohorts (18.7% vs. 31.5%, p=0.11). There was no difference in terms of transfusion requirement, febrile neutropenia episodes or the need for antifungal use during the treatment cycles in the propensity-matched cohort. The median overall survival was 20.4 months for azacitidine and 16.8 months for decitabine (p=0.59). Finally, we found that at least a four-cycle treatment with any HMA was a favorable factor. In conclusion, both azacitidine and decitabine have similar efficacy and toxicity profiles in the treatment of MDS-RAEB.
(Copyright © 2016 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: